Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)

By sjmartinez • August 16, 2023

Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Bengtsson T, Rickard K, Sciurba F. Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials). Am J Respir Crit Care Med. 2023 Aug 15;208(4):406-416. doi: 10.1164/rccm.202306-0944OC. PMID: 37364283.

Tags: COPD, dual PDE3 and PDE4 inhibitor, ensifentrine, nebulized therapy, Publications, Pulmonary, Critical Care & Sleep Medicine

Predicting Oral HIV Pre-Exposure Prophylaxis Efficacy in Cisgender Women Across Pregnancy and Postpartum

Yu Y, Brooks KM, Doncel GF, Best BM, Marzinke MA, Mirochnick M, Anderson PL, Myer L, Celum C, Heffron R, Coleman J, Davey DLJ, Zhang[...]

Association between Alzheimer’s disease-related genes and neurodegenerative blood-based biomarkers in Indian adults

Abu-Amara H, Zhao W, Li Z, Leung YY, Schellenberg GD, Wang LS, Crimmins EM, Thyagarajan B, Anwar M, Hu P, Dey S, Dey AB, Zhou[...]

Metastatic Melanoma Presenting As Small Bowel Obstruction

Ruci A, Chan SM, Kan CK, Fagel C, Maque J. Metastatic Melanoma Presenting As Small Bowel Obstruction. Cureus. 2026 Aug 2;18(8):e113827. doi: 10.7759/cureus.113827. PMID: 42688324;[...]